Navigation Links
PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
Date:9/9/2013

thin the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "will"; "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. Such statements include, but are not limited to those referring to the potential for the generation of value, ability to leverage funding sources, potential for revenue, and potential for growth.  PharmAthene disclaims any intent or obligation to update these forward-looking statements.  Risks and uncertainties include, among others, failure to obtain necessary shareholder approval for the proposed merger with Theraclone and the matters related thereto; failure of either party to meet the conditions to closing of the transaction; delays in completing the transaction and the risk that the transaction may not be completed at all; failure to realize the anticipated benefits from the transaction or delay in realization thereof; the businesses of PharmAthene and Theraclone may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; operating costs and business disruption during the pendency of and following the transaction, including adverse effects on employee retention and on business relationships with third parties; the combined company's need for and ability to obtain additional financing; risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the combined company's product candidates; unexpected funding delays and/or reductions o
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. PharmAthene Reports Year-End 2012 Financial And Operational Results
10. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
11. PharmAthene to Host Second Quarter 2013 Conference Call and Webcast on Wednesday, August 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Sterlitech is proud to announce that it ... stable of products . These additional products increase ... membrane filters with surface charges. , “We ... our membrane process testing equipment, and correspondingly, a wider ... explains Sterlitech President Mark Spatz. “The addition of ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... a Florida State University research team has led to ... emit white light, and convert photon energy directly to ... butterfly. , Biwu Ma, associate professor in the Department ... of Engineering, created the molecule in a lab about ... his creation has many other unique capabilities. , For ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... DNDN ) today announced that management will participate ... Life Sciences Conference Grand Hyatt New York ... The presentation will be audio webcast live and available ... Corporation is a biotechnology company whose mission is to,target ...
... Sept. 18 Premier Research Group plc (AIM:,PRG) ... its Vice President,Global Human Resources. Mr. Keenen will ... activities related to maximizing the,effectiveness of Premier Research,s ... strategy. Dr. Troy McCall, COO, commented: "We ...
... places Bioscrypt,s fingerprint reader on biometrics access control ... approved products list for airports, ... a,leading provider of enterprise access control technology, today announced,that its ... (TSA) and placed on the TSA,s "Biometrics for,Access Control" Qualified ...
Cached Biology Technology:Premier Research Appoints Global Head of Human Resources 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 3
(Date:8/27/2014)... but deadly disease that exists as five strains, none ... lethal strains is the Sudan ebolavirus (SUDV). Although not ... widespread illness, even as recently as 2012. In a ... Biology , researchers now report a possible therapy that ... John Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain ...
(Date:8/27/2014)... traps are lost or abandoned each year in U.S. ... which continue to catch fish, crabs, and other species ... habitat, fisheries, and the watermen who depend on the ... published NOAA study. , The report, published in the ... its kind to examine the derelict fish trap problem, ...
(Date:8/27/2014)... Adelaide research has shown that piglets can be weaned ... , The outcome of the study at the University,s ... Science , is an important finding for pig producers. ... loss of production. , "Sows don,t usually start their ... after their piglets have been weaned," says Ms Alice ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2Piglet weaning age no bar to litter frequency 2
... is available in French . , ... chilli cook-off, usually has a key secret ingredient, which ... proteins, which change the dynamics of cells from benign ... McGill University, the Research Institute of the McGill University ...
... in French . , Montreal, May 19th ... to humans, and its abuse has become widespread since the ... know rather little about its effects on the human brain ... article by Dr. Marco Leyton, of the Montreal Neurological Institute ...
... critical to insulating the wiring that connects the brain and ... diseases, from rare ones that lower the pain threshold to ... this week in Proceedings of the National Academy of ... system that controls arms and legs, the protein erbin regulates ...
Cached Biology News:Proteomics: Finding the key ingredients of disease 2Cocaine: Perceived as a reward by the brain? 2Protein identified as critical to insulating the body's wiring could also become treatment target 2
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.45 micron filtration, ... This formulation insures consistently high levels of ...
... utilizies CTI Molecular Imaging's proprietary Focus™ ... sensitivty, and a large imaging volume ... to image multiple mice or large ... a dedicated small animal PET (Positron ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
384 Well PCR Plate Carrier for Thermo-Sealer...
Biology Products: